http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
VolitionRx (VNRX) Presents Results from 8000 Patient Trial in Denmark Evaluating Performance of its Nu.Q Triage Test
-
VolitionRx Limited Announces Final Results from 8000 Patient Clinical Trial in Denmark to Evaluate the Performance of its Nu.Q(TM) Triage Test
-
VolitionRx Limited Schedules First Quarter 2017 Earnings Conference Call and Business Update
-
Volition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe
-
Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory
-
Volitionrx Limited (VNRX) Appoints David Vanston as CFO
-
VolitionRx Appoints David Vanston as Chief Financial Officer
-
Volitionrx Limited (VNRX) Retains Strategic Consultant to Secure Non-Dilutive Funding Opportunities
-
Volition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States
-
Volitionrx Limited (VNRX) Forms Wholly-Owned U.S. Subsidiary
-
VolitionRx Limited Announces the Formation of Volition America, Inc.
-
VolitionRx Limited to Ring the New York Stock Exchange Closing Bell on Monday, March 13th at 4 pm Eastern Daylight Time
-
VolitionRx Limited Announces Full Fiscal Year 2016 Financial Results and Business Update
-
VolitionRx Limited to Present at the 29th Annual ROTH Conference
-
VolitionRx Limited Schedules Fourth Quarter and Full Year 2016 Earnings Conference Call and Business Update
-
A Logistics and Pathway Design Study for Volition's CE Marked NuQ(TM) Triage Test has been Commenced in the Capital Region of Denmark
-
VolitionRx Limited's Triage Test Results Validated in Prospective Trial
-
VolitionRx Limited to Attend the BTIG 2017 Medical Technology, Life Sciences, and Diagnostics Conference
-
VolitionRx Limited to Present at Source Capital Group's 2nd Annual Disruptive Growth & Healthcare Conference on February 15, 2017
-
VolitionRx Limited Strengthens Team with Key Appointment to Drive Sales and Trials in Asia
-
VolitionRx Limited's Novel Cancer Diagnostic Test Achieves CE Marking as it Prepares for Launch Across Europe
-
VolitionRx Limited to Present at 9th Annual Biotech Showcase Conference
-
VolitionRx Limited to Attend Citi 2016 Global Healthcare Conference
-
VolitionRx Limited to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2016
-
VolitionRx Limited Announces Third Quarter 2016 Financial Results and Business Update
-
VolitionRx Limited Schedules Third Quarter 2016 Earnings Conference Call and Business Update
-
Volitionrx Limited (VNRX), Hvidovre Hospital Enter Cancer Blood Tests Clinical Study
-
VolitionRx Limited and Hvidovre Hospital Begin Large Prospective Clinical Study
-
VolitionRx Limited Announces Acquisition of New Belgian Facility and Appointment of COO to Belgian Volition
-
VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriter
-
Triage Blood Test Data Presented to Leading International Experts at the World Endoscopy Organization's Colorectal Cancer Screening Committee
-
Volitionrx Limited (VNRX) Announces Presentation of Positive Blood Test for Colorectal Cancer Data
-
Data Presented at ESMO 2016 Demonstrates that VolitionRx Limited's Novel Blood Test for Colorectal Cancer Potentially Reduces the Need for Colonoscopy Referral by 25%
-
VolitionRx Limited Announces Closing of Public Offering of Common Stock
-
Volitionrx Limited (VNRX) Prices 2.25M Common Stock Offering at $5/Share
-
VolitionRx Limited Announces Pricing of Public Offering of Common Stock
-
Volitionrx Limited (VNRX) to Offer Common Stock
-
VolitionRx Limited Announces Proposed Public Offering of Common Stock
-
VolitionRx to Attend Several Conferences in September
-
VolitionRx to Attend Several Conferences in September
-
Volition's Nu.Q Triage Colorectal Cancer Screening Test Expected to Reduce Colonoscopy Referral by 25 Percent
-
Volition's Nu.Q Triage Colorectal Cancer Screening Test Expected to Reduce Colonoscopy Referral by 25 Percent
-
VolitionRx Schedules Product Launch Update Conference Call for Tuesday, September 6, 2016 at 8:30 am ET
-
VolitionRx Schedules Product Launch Update Conference Call for Tuesday, September 6, 2016 at 8:30 am ET
-
VolitionRx Announces Second Quarter 2016 Financial Results and Business Update
-
VolitionRx Schedules Second Quarter 2016 Earnings Conference Call and Business Update for Thursday, August 11, 2016 at 8:30am ET
-
VolitionRx Engages Edison Advisors as Investor Relations Counsel
-
VolitionRx Granted Fourth U.S. Patent
-
VolitionRx Appoints Dr. Edward Futcher to Board of Directors
-
Volitionrx Limited (VNRX) Announces Publication of Positive NuQ Blood Test Assessment Data

